Surrogate End Points,Skepticism,and the CAST Study

Temple R . Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282: 790–5.

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.

Psaty BM Weiss NS Furberg CD Koepsell TD Siscovick DS Rosendaal FR . Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999; 282: 786–90.

Fleming TR DeMets DL . Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996;125: 605–13.

Colburn WA . Surrogate markers and clinical pharmacology (commentary). J Clin Pharmacol 2001; 35: 441–2.

Sobel BE Furberg CD . Surrogates, semantics, and sensible public policy (commentary). Circulation 1997; 95: 1661–3.

Califf RM Kramer JM . What have we learned from the calcium channel blocker controversy? (editorial). Circulation 1998; 97: 1529–31.

Kaplan NM . Should new drugs be used without outcome data? Implications of ALLHAT and ELITE II (commentary). Arch Intern Med 2001; 161; 511–2.

Pratt CM Moye L . The cardiac arrhythmia suppression trial: Implications for antiarrhythmic drug development. J Clin Pharmacol 1990; 30: 967–74.

Bauman JL . Results of the CAST…what did we catch? (letter). Pharmacotherapy 1989; 9: 267–8.

Hasegawa GR . Antiarrhythmic therapy: Reminders from CAST (editorial). Clin Pharm 1989; 8: 509.

Alpert JS Coles R . Loss of skepticism in medical education (editorial). Arch Intern Med 1989; 149: 2637–8.